SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…
Availity’s Intelligent Utilization Management delivers on health plans’ ambitious visionJACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity, the nation’s largest…
Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…
Company closes $4.54M in Seed round led by Caduceus Capital Partners, with participation from Bread…
BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early…